Protagonist Therapeutics, Inc
PTGX Real Time Price USDRecent trades of PTGX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PTGX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
PTGX Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jan. 30, 2024
-
Patent Title: Α4β7 thioether peptide dimer antagonists Dec. 12, 2023
-
Patent Title: Hepcidin analogues and uses thereof Nov. 07, 2023
-
Patent Title: Conjugated hepcidin mimetics Sep. 12, 2023
-
Patent Title: Analogues of hepcidin mimetics with improved in vivo half lives Oct. 18, 2022
-
Patent Title: Α4α7 peptide monomer and dimer antagonists Sep. 07, 2021
-
Patent Title: Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Jun. 22, 2021
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Mar. 09, 2021
-
Patent Title: Opioid agonist peptides and uses thereof Aug. 04, 2020
-
Patent Title: Hepcidin analogues and uses thereof Dec. 10, 2019
-
Patent Title: Hepcidin analogues and uses thereof Oct. 15, 2019
-
Patent Title: Methods for synthesizing α4β7 peptide antagonists Sep. 10, 2019
-
Patent Title: Cyclic monomer and dimer peptides having integrin antagonist activity May. 28, 2019
-
Patent Title: Opioid agonist peptides and uses thereof May. 07, 2019
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Feb. 05, 2019
-
Patent Title: Α4β7 thioether peptide dimer antagonists Aug. 28, 2018
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 31, 2018
-
Patent Title: Hepcidin analogues and uses thereof Jul. 24, 2018
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 17, 2018
-
Patent Title: Hepcidin analogues and uses thereof Nov. 21, 2017
-
Patent Title: Α4β7 peptide monomer and dimer antagonists Nov. 07, 2017
-
Patent Title: A4b7 integrin thioether peptide antagonists Jul. 25, 2017
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Apr. 18, 2017
-
Patent Title: Α4β7 peptide dimer antagonists Mar. 01, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to PTGX
Number of mentions of PTGX in WallStreetBets Daily Discussion
Recent picks made for PTGX stock on CNBC
ETFs with the largest estimated holdings in PTGX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PTGX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.